Gerrit Schreij

736 total citations
27 papers, 572 citations indexed

About

Gerrit Schreij is a scholar working on Infectious Diseases, Pulmonary and Respiratory Medicine and Virology. According to data from OpenAlex, Gerrit Schreij has authored 27 papers receiving a total of 572 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Virology. Recurrent topics in Gerrit Schreij's work include HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (9 papers) and HIV/AIDS Research and Interventions (9 papers). Gerrit Schreij is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (9 papers) and HIV/AIDS Research and Interventions (9 papers). Gerrit Schreij collaborates with scholars based in Netherlands, United States and Czechia. Gerrit Schreij's co-authors include Joep M. A. Lange, Ingeborg Engelberts, Jan H.M. Tordoir, Richard M. W. Hoetelmans, Jan W. Mulder, Agnes I. Veldkamp, Jos H. Beijnen, Patricia W. H. Hugen, David M. Burger and Rob E. Aarnoutse and has published in prestigious journals such as Neurology, Clinical Infectious Diseases and Hypertension.

In The Last Decade

Gerrit Schreij

27 papers receiving 546 citations

Peers

Countries citing papers authored by Gerrit Schreij

Since Specialization

Citations

This map shows the geographic impact of Gerrit Schreij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerrit Schreij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerrit Schreij more than expected).

Fields of papers citing papers by Gerrit Schreij

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerrit Schreij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerrit Schreij. The network helps show where Gerrit Schreij may publish in the future.

Co-authorship network of co-authors of Gerrit Schreij

This figure shows the co-authorship network connecting the top 25 collaborators of Gerrit Schreij. A scholar is included among the top collaborators of Gerrit Schreij based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerrit Schreij. Gerrit Schreij is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management. 2011 ·PubMed ·Joop E. Arends, Femke A.E. Lambers, Jan T. M. van der Meer, Gerrit Schreij, Clemens Richter, Kees Brinkman, Andy I. M. Hoepelman, (unknown)	9
2	InforMatrix nucleoside/nucleotide reverse transcriptase inhibitor ‘backbones’ 2007 ·Expert Opinion on Pharmacotherapy ·Gerrit Schreij, Robert Janknegt	2
3	Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naive adults 2005 ·Clinical Trials ·(unknown), Amj Wensing, (unknown), (unknown), Clemens Richter, Gerrit Schreij, Petra C. Koopmans, (unknown), Ingeborg van der Tweel, J Lange, Jan C.C. Borleffs	3
4	Comparison of Two Once-Daily Regimens with a Regimen Consisting of Nelfinavir, Didanosine, and Stavudine in Antiretroviral Therapy-Naïve Adults: 48-Week Results from the Antiretroviral Regimen Evaluation Study (ARES) 2005 ·HIV Clinical Trials ·S.H. Lowe, Annemarie M. J. Wensing, Elly A. Hassink, Reinier W. ten Kate, Clemens Richter, Gerrit Schreij, P.P. Koopmans, J.R. Juttmann, Ingeborg van der Tweel, Joep M. A. Lange, Jan C.C. Borleffs	6
5	Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals 2003 ·AIDS ·David M. Burger, Patricia W. H. Hugen, Peter Reiss, Inge C. Gyssens, M. M. E. Schneider, Frank P. Kroon, Gerrit Schreij, Kees Brinkman, Clemens Richter, Jan M. Prins, Rob E. Aarnoutse, Joep M. A. Lange	119
6	A delay in CD4 cell response after initiation of highly active antiretroviral therapy is associated with the presence of anti-cytomegalovirus but not with anti-herpes simplex virus antibodies 2002 ·AIDS ·Valère J. Goossens, Gerrit Schreij, Siebe van der Geest, (unknown), Dominique C. Baas, Cathrien A. Bruggeman, André van der Ven	7
7	Steady-State Pharmacokinetics of Twice-Daily Dosing of Saquinavir Plus Ritonavir in HIV-1–Infected Individuals 2001 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Agnes I. Veldkamp, (unknown), Jan W. Mulder, P. L. Meenhorst, Gerrit Schreij, Sjaak van der Geest, Joep M. A. Lange, Jos H. Beijnen, Richard M. W. Hoetelmans	42
8	Overwhelming CNS cryptococcus in AIDS 2001 ·Neurology ·(unknown), Pieter Hofman, Gerrit Schreij, FJ Bot, (unknown)	3
9	Steady-State Pharmacokinetics of Twice-Daily Dosing of Saquinavir Plus Ritonavir in HIV-1–Infected Individuals 2001 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Agnes I. Veldkamp, Rolf P. G. van Heeswijk, Jan W. Mulder, Pieter L. Meenhorst, Gerrit Schreij, Siebe van der Geest, Joep M. A. Lange, Jos H. Beijnen, Richard M. W. Hoetelmans	10
10	The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals 1999 ·AIDS ·Rolf P. G. van Heeswijk, Agnes I. Veldkamp, Richard M. W. Hoetelmans, Jan W. Mulder, Gerrit Schreij, Ann Hsu, Joep M. A. Lange, Jos H. Beijnen, Pieter L. Meenhorst	95
11	Quantitative Residual Cortical Activity Measurement: Appropriate Test for Diagnosis of Renal Artery Stenosis? 1999 ·Urologia Internationalis ·(unknown), Ahmet Reşit Ersay, (unknown), (unknown), Gerrit Schreij, (unknown)	4
12	Acute Respiratory Failure Associated with the Human Immunodeficiency Virus (HIV) Protease Inhibitor Indinavir in an HIV‐Infected Patient 1998 ·Clinical Infectious Diseases ·J. Dieleman, (unknown), Jan C.C. Borleffs, Gerrit Schreij	2
13	Concealed lung abscess in critically ill, mechanically ventilated patients 1996 ·The Netherlands Journal of Medicine ·(unknown), (unknown), Claudia Langenberg, Gerrit Schreij	3
14	Patterns of morbidity and mortality in AIDS patients on prophylaxis who died during hospital admission: A report of 50 diseased patients 1996 ·The Netherlands Journal of Medicine ·(unknown), Gerrit Schreij	5
15	Stenosis and renographic characteristics in renovascular disease. 1996 ·PubMed ·Gerrit Schreij, (unknown), Gerard Vreugdenhil, Peter W. de Leeuw	9
16	Baseline and postcaptopril renal blood flow measurements in hypertensives suspected of renal artery stenosis. 1996 ·PubMed ·Gerrit Schreij, (unknown), Marinus J.P.G. van Kroonenburgh, Gerrit J. Kemerink, G. A. K. Heidendal, Peter W. de Leeuw	7
17	High-Output Cardiac Failure due to Excessive Shunting in a Hemodialysis Access Fistula: An Easily Overlooked Diagnosis 1995 ·American Journal of Nephrology ·Ingeborg Engelberts, Jan H.M. Tordoir, (unknown), Gerrit Schreij	94
18	Interpretation of captopril renography by nuclear medicine physicians. 1995 ·PubMed ·Gerrit Schreij, (unknown), (unknown), (unknown), Peter W. de Leeuw	6
19	Renal Arterial and Venous Endothelin in Hypertensive Patients with or Without Renal Artery Stenosis 1994 ·Blood Pressure ·Gerrit Schreij, (unknown), Paul Schiffers, Peter W. de Leeuw	4
20	Zidovudine and Interferon- Combination Therapy versus Zidovudine Monotherapy in Subjects with Symptomatic Human Immunodeficiency Virus Type 1 Infection 1994 ·The Journal of Infectious Diseases ·P. H. J. Frissen, Marc van der Valk, Chris H.H. ten Napel, H Weigel, Gerrit Schreij, (unknown), P.P. Koopmans, Andy I. M. Hoepelman, Josien B. de Boer, Gerrit‐Jan Weverling, (unknown), Pauline M. Dowd, Frank Miedema, (unknown), Charles A. Boucher, J. M. A. Lange	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact